Erik Holmberg
YOU?
Author Swipe
View article: Supplementary Figure S1 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Supplementary Figure S1 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial Open
Gene sets from the molecular signatures database were used to create a model measuring immunological activity and immunomodulatory tumor-intrinsic factors. These were merged to create a model considering the interaction between the antitum…
View article: Study protocol S1 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Study protocol S1 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial Open
Protocol for original SweBCG91RT trial
View article: Supplementary Figure S2 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Supplementary Figure S2 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial Open
Immunescore (A), developed in this manuscript, showed a stronger correlation with tumor-infiltrating lymphocytes than other developed methods (B and C) to quantify the degree of immune infiltration.
View article: Supplementary Tables S5-S11 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Supplementary Tables S5-S11 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial Open
Supplementary MethodsTable S5. Clinical characteristics of the Sjöström and Servant cohortsTable S6. Comparison of included versus excluded patientsTable S7. 10-year follow-up for local recurrence (IBTR). Flexible parametric survival analy…
View article: Supplementary Figure S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
Supplementary Figure S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial Open
The interaction between the Integrated model and RT was significant in an unadjusted analysis (p=0.004) and an analysis adjusted for histological grade, age, ER status, and tumor size (p=0.008). The figure shows the predicted 10-year cumul…
View article: A Randomised Clinical Trial Comparing Two Biopsy Templates and Follow-up Schedules for Men on Active Surveillance for Low-risk Prostate Cancer: SAMS
A Randomised Clinical Trial Comparing Two Biopsy Templates and Follow-up Schedules for Men on Active Surveillance for Low-risk Prostate Cancer: SAMS Open
Background and objective: Neither the number nor location of biopsy cores or follow-up schedules for active surveillance of prostate cancer are based on evidence from randomised trials. We therefore initiated a study that compared two foll…
View article: Exploring endometrial cancer in premenopausal women—A nationwide <scp>PremEnCa</scp> cohort study
Exploring endometrial cancer in premenopausal women—A nationwide <span>PremEnCa</span> cohort study Open
Introduction An increased incidence of endometrial cancer has been noted, especially in premenopausal women in countries with rapid socioeconomic transition. In one of the largest patient cohorts of women ≤50 years, with manually validated…
View article: Primary treatment and survival in malignant ovarian germ cell tumors: A nationwide population-based Swedish Gynecologic Cancer Group (SweGCG) study
Primary treatment and survival in malignant ovarian germ cell tumors: A nationwide population-based Swedish Gynecologic Cancer Group (SweGCG) study Open
MOGCTs had excellent survival outcomes in this nationwide population-based study, and fertility-sparing surgery was deemed safe. Future efforts should focus on improving outcomes in older women and those with stage IV disease.
View article: Navigating the Border - How Swedish Physicians Approach Palliative Care Referrals in Oncology
Navigating the Border - How Swedish Physicians Approach Palliative Care Referrals in Oncology Open
Introduction Early integration of palliative care (PC) alongside oncology care is widely recognised as beneficial for patients and their next of kin. Sharing the responsibility with colleagues can ease the burden for the physician. However…
View article: Predicting immune responsiveness in ER-positive breast cancer for personalized therapy: a population-based study
Predicting immune responsiveness in ER-positive breast cancer for personalized therapy: a population-based study Open
The immune system’s role in estrogen receptor (ER)-positive breast cancer is poorly understood. A population-based cohort of 428 breast cancer patients with clinical and molecular data was analyzed to assess how immune biomarkers can infor…
View article: Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial
Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial Open
Background/Aim The TGF-β pathway can influence breast cancer progression and therapy efficacy, exhibiting both pro- and anti-tumoral effects. This study examined the impact of active TGF-β signaling on recurrence and radiotherapy (RT) bene…
View article: Validation of data quality in the Swedish quality register of gynecologic cancer for cervical cancer and vulvar cancer—a Swedish gynecologic cancer group (Swe‐<scp>GCG</scp>) study
Validation of data quality in the Swedish quality register of gynecologic cancer for cervical cancer and vulvar cancer—a Swedish gynecologic cancer group (Swe‐<span>GCG</span>) study Open
Introduction Population‐based registers provide an important source of real‐world data. The growing number of large cohort studies using data from cancer registers makes validation of such registers important. The Swedish Quality Register …
View article: Survival outcomes in hormone receptor-negative breast cancer among BRCA carriers versus noncarriers in western Sweden
Survival outcomes in hormone receptor-negative breast cancer among BRCA carriers versus noncarriers in western Sweden Open
Background and purpose: BRCA-related hormone receptor (HR)-negative breast cancers (BC) are reported to have aggressive tumor biology but also exhibit chemosensitivity. However, the impact of BRCA1/2 pathogenetic variants (PV) on BC outcom…
View article: Supplementary Table S2 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Supplementary Table S2 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Median and interquartile ranges for each pY397-FAK variable as distributed across the NoRT and RT arms
View article: Supplementary Table S1 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Supplementary Table S1 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Table of Antibodies. List of primary, conjugated and secondary antibodies stained for in each round: CD31, α-SMA, Pan-CK and pY397-FAK.
View article: Supplementary Figure S4 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Supplementary Figure S4 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Spearman’s rank correlations (A) Spearman’s rank correlations of patient characteristics and pY397-FAK scores for EC, TC and ααSMA region. Upper figures, r-values; lower figures p-values. (B) No correlation between EC_ pY397-FAK and CD31+ …
View article: Supplementary Table S7 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Supplementary Table S7 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Outcome is all recurrence for αSMA_pY397-FAK, 5-year follow-up.
View article: Supplementary Figure S3 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Supplementary Figure S3 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Immunofluorescence staining for pY397-FAK, CD31, PanCK and αSMA. Representative immunofluorescence images of a patient in the highest and lowest quartiles of pY397-FAK intensity, in the CD31-positively stained endothelial cells (EC_ pY397-…
View article: Data from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Data from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Purpose:Identifying biomarkers of radiotherapy (RT) response is important for optimizing the treatment of early breast cancer. In this study, we tested the interaction between endothelial cell (EC) expression of phospho-Tyr397-FAK (pY397-F…
View article: Supplementary Table S3 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Supplementary Table S3 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Representativeness of Study participants
View article: Supplementary Table S4 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Supplementary Table S4 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Outcome is locoregional recurrence for TC_pY397-FAK, 5-year follow-up.
View article: Supplementary Table S5 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Supplementary Table S5 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Outcome is all recurrence for TC_pY397-FAK, 5-year follow-up.
View article: Supplementary Figure S2 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Supplementary Figure S2 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Distribution of average pY397-FAK intensity scores. Data are given per patient, from primary tumour cores only, in the CD31+ endothelial cells (A), panCK+ tumour cells (B) and ααSMA+ region (C), and average CD31 positive-stained blood vess…
View article: Supplementary Figure S1 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Supplementary Figure S1 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Graphical summary of the Cell DIVE and HALO analysis methods used for measuring pY397-FAK intensity patient tissue microarrays (TMAs). CAFs, Cancer-associated fibroblasts; H&Es, Haemotoxylin and Eosin; ROI, Region-of-interest; QC, Quality …
View article: Supplementary Table S6 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Supplementary Table S6 from Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Outcome is locoregional recurrence for αSMA_pY397-FAK, 5-year follow-up
View article: Extracellular vesicles in lung donor plasma: Potential indicators of donor organ quality
Extracellular vesicles in lung donor plasma: Potential indicators of donor organ quality Open
Donor plasma EVs carry distinct transcriptomic signatures associated with injury and inflammation. Specific EV transcripts, such as RAD51D and XG, hold promise as independent predictive biomarkers for PGD, possibly providing new tools for …
View article: The potential radiosensitization target PFKFB3 is related to response to radiotherapy in SweBCG91RT: a randomized clinical trial with long-term follow-up
The potential radiosensitization target PFKFB3 is related to response to radiotherapy in SweBCG91RT: a randomized clinical trial with long-term follow-up Open
View article: Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort
Endothelial Cell pY397-FAK Expression Predicts the Risk of Breast Cancer Recurrences after Radiotherapy in the SweBCG91-RT Cohort Open
Purpose: Identifying biomarkers of radiotherapy (RT) response is important for optimizing the treatment of early breast cancer. In this study, we tested the interaction between endothelial cell (EC) expression of phospho-Tyr397-FAK (pY397-…
View article: Risks and use of ERCP during the diagnostic workup in a national cohort of biliary cancer
Risks and use of ERCP during the diagnostic workup in a national cohort of biliary cancer Open
Background In biliary cancer, the indication of endoscopic intervention might be diagnostic as well as therapeutic, in the latter situation with the aim to relieve biliary obstruction e.g. by stenting. Our aim was to investigate the use of…
View article: Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis Open
Background There are currently no molecular tests to identify individual breast cancers where radiotherapy (RT) offers no benefit. Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) is a 16-gene molecular signature developed t…